Multistate cannabis operator (MSO) PharmaCann is making a significant retreat from Colorado, signaling broader challenges facing operators in one of the nation’s most mature cannabis markets.
The Chicago-based company has confirmed it will close its Denver cultivation and processing facility on May 20, resulting in the layoff of 132 employees. The move appears to mark PharmaCann’s full exit from the Colorado market, just four years after entering the state during the height of the cannabis boom.
From Expansion to Exit
PharmaCann entered Colorado in 2022 through its acquisition of LivWell Enlightened Health, a deal that dramatically expanded its footprint across key U.S. cannabis markets. At the time, the merger was seen as a strategic move to capitalize on strong pandemic-era sales and position the company as a dominant multistate operator.
Colorado had just recorded more than $2.2 billion in annual dispensary sales, making it one of the most lucrative cannabis markets in the country. The acquisition gave PharmaCann access to a robust retail and cultivation network, increasing its national presence to more than 50 dispensaries and 10 production facilities across eight states.
However, the optimism that defined that era has since faded.
Price Compression and Market Contraction
Colorado’s cannabis market has undergone a sharp correction since 2021. Retail sales have declined approximately 41%, falling to $1.3 billion in 2025. At the same time, wholesale and retail prices have dropped to historic lows.
The average wholesale price for cannabis flower has plummeted from a peak of $1,721 per pound in 2021 to roughly $607 today – a decline of more than 65%. Retail prices have followed suit, with average flower prices hovering around $3.12 per gram.
This level of price compression has made it increasingly difficult for operators – especially those with large-scale cultivation facilities – to maintain profitability.
PharmaCann’s Denver facility, a nearly 190,000-square-foot operation, represents one of the largest licensed grows in the state. Its closure reflects a growing trend: scaling back or eliminating cultivation in oversupplied markets where buying wholesale cannabis is now more cost-effective than growing it in-house.
Strategic Divestment and Financial Pressures
The cultivation shutdown follows PharmaCann’s December agreement to sell its 17 Colorado dispensaries, previously operating under the LivWell brand, to Vireo Growth Inc. in a $49 million stock deal.
The company has also faced mounting financial challenges, including lease defaults tied to properties managed by Innovative Industrial Properties (IIP). A recent settlement requires PharmaCann to relinquish several facilities across multiple states, further underscoring the company’s need to streamline operations and reduce liabilities.
These developments suggest that PharmaCann may have overextended during the industry’s expansion phase and is now recalibrating amid a more challenging economic environment.
Vireo Growth Doubles Down on Retail
While PharmaCann retreats, other operators are taking a different approach.
Vireo Growth has emerged as Colorado’s largest cannabis retailer following its acquisition of PharmaCann’s dispensaries. The company now operates approximately 55 stores across the state and has indicated interest in pursuing additional acquisitions.
Notably, Vireo’s strategy emphasizes retail expansion over cultivation ownership. Like many operators, the company appears to be leaning into an asset-light model, favoring wholesale purchasing over the high costs associated with large-scale growing operations.
Vireo has selectively expanded its production capacity through targeted acquisitions, including facilities obtained through its $111 million credit bid for Denver-based Schwazze. However, its broader approach reflects a shift in how companies are navigating today’s cannabis economics.
A Changing Landscape in Colorado
PharmaCann’s exit highlights a broader contraction in Colorado’s cannabis cultivation sector. The number of licensed adult-use cultivators has dropped significantly—from 817 in mid-2022 to roughly 470 today.
This consolidation reflects an industry-wide reset as operators adjust to lower prices, reduced demand growth, and tighter access to capital.
For many businesses, survival now depends on operational efficiency, strategic focus, and the ability to adapt to rapidly changing market conditions.
Preparing for What’s Next in Cannabis
As market conditions continue to evolve, cannabis operators must stay agile, informed, and prepared for both challenges and new opportunities.
Whether you’re navigating market downturns, considering expansion, or restructuring your operations, Canna Business Services (CBS) is here to help. Our team provides expert guidance on licensing, compliance, financial strategy, and operational planning tailored to today’s cannabis landscape.
Even in uncertain markets, preparation is key. Reach out to CBS today to ensure your business is positioned for long-term success, no matter where the industry heads next.
